 | |
- close
- close
|
Business Wire
Nov 24
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced the closing of its underwritten public offering of 4,726,027 shares of its common stock, which includes the full exercise of the underwriter’s overallotment option of 616,438 shares. The net proceeds to
StreetInsider.com
Nov 19
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Affymax+%28AFFY%29+Prices+4.1M+Shares+at+%2418.25Share/5125867.html for the full story.
Business Wire
Nov 19
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced that it has priced an underwritten public offering of 4,109,589 shares of its common stock at a price of $18.25 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated
Business Wire
Nov 18
Comment
Affymax, Inc. (Nasdaq: AFFY), today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. Affymax expects to grant the underwriters a thirty-day option to purchase
Business Wire
Nov 10
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide™, has completed its final scheduled review and has informed the company that the
Business Wire
Nov 4
Comment
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need for
StreetInsider.com
Nov 4
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Affymax+%28AFFY%29+Posts+Q3+Loss+of+%240.97%2C+Narrower+than+Expected/5073153.html for the full story.
Business Wire
Nov 4
Comment
Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008. Affymax
Business Wire
Nov 3
Comment
Affymax, Inc. (Nasdaq:AFFY) today announced the appointment of Hollings C. Renton to the position of chairman of the company’s board of directors effective December 1, 2009. Mr. Renton replaces Nick Galakatos, who served as lead board member since
Business Wire
Oct 30
Comment
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
AFFY AT A GLANCE
References
| ||||||
|
|
